HRP20200478T1 - Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda - Google Patents

Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda Download PDF

Info

Publication number
HRP20200478T1
HRP20200478T1 HRP20200478TT HRP20200478T HRP20200478T1 HR P20200478 T1 HRP20200478 T1 HR P20200478T1 HR P20200478T T HRP20200478T T HR P20200478TT HR P20200478 T HRP20200478 T HR P20200478T HR P20200478 T1 HRP20200478 T1 HR P20200478T1
Authority
HR
Croatia
Prior art keywords
compound
formula
alkyl
compound according
pharmaceutically acceptable
Prior art date
Application number
HRP20200478TT
Other languages
English (en)
Croatian (hr)
Inventor
Kim D. Janda
Nicholas T. JACOB
Jonathan W. LOCKNER
Original Assignee
The Scripps Research Institute La Jolla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute La Jolla filed Critical The Scripps Research Institute La Jolla
Publication of HRP20200478T1 publication Critical patent/HRP20200478T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20200478TT 2014-03-31 2015-03-30 Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda HRP20200478T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31
EP15772254.7A EP3125898B1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction
PCT/US2015/023362 WO2015153468A1 (en) 2014-03-31 2015-03-30 Pharmacophore for trail induction

Publications (1)

Publication Number Publication Date
HRP20200478T1 true HRP20200478T1 (hr) 2020-07-24

Family

ID=54241169

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20200478TT HRP20200478T1 (hr) 2014-03-31 2015-03-30 Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda
HRP20241680TT HRP20241680T1 (hr) 2014-03-31 2015-03-30 Farmakofor za trail indukciju

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20241680TT HRP20241680T1 (hr) 2014-03-31 2015-03-30 Farmakofor za trail indukciju

Country Status (20)

Country Link
US (5) US10239877B2 (enExample)
EP (3) EP3662910B1 (enExample)
JP (4) JP6756435B2 (enExample)
KR (2) KR102611067B1 (enExample)
CN (2) CN106456643B (enExample)
AU (4) AU2015241069B2 (enExample)
CA (2) CA3158795A1 (enExample)
CY (1) CY1123093T1 (enExample)
DK (2) DK3662910T3 (enExample)
ES (2) ES2999685T3 (enExample)
FI (1) FI3662910T3 (enExample)
HR (2) HRP20200478T1 (enExample)
HU (2) HUE049013T2 (enExample)
LT (2) LT3125898T (enExample)
PL (2) PL3662910T3 (enExample)
PT (2) PT3125898T (enExample)
RS (2) RS66254B1 (enExample)
SI (2) SI3125898T1 (enExample)
SM (2) SMT202400497T1 (enExample)
WO (1) WO2015153468A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9265765B2 (en) 2013-03-13 2016-02-23 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
CN110669047A (zh) * 2013-11-15 2020-01-10 昂克希尔迪克斯有限公司 用于治疗癌症的化合物、其组合物及应用方法
RS66254B1 (sr) 2014-03-31 2024-12-31 Scripps Research Inst Farmakofor koji indukuje trail
SI3805222T1 (sl) * 2015-01-30 2025-04-30 Oncoceutics, Inc. Derivati 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a] pirido[3,4-e]pirimidin-5(1H)-ona, njihove soli in njihova uporaba v terapiji
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
CN115844895B (zh) * 2016-01-29 2025-10-17 昂克希尔迪克斯有限公司 依米立酮化合物在制备用于治疗中枢神经系统癌症的药物中的用途
US11091483B2 (en) 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
CN113795251B (zh) 2019-02-27 2026-01-13 马德拉治疗公司 酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途
EP4192467A1 (en) 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途
EP4684834A1 (de) * 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
JP2006506401A (ja) * 2002-05-23 2006-02-23 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害薬
DK2303264T3 (en) * 2008-06-09 2018-05-22 Allergan Inc METHODS FOR TREATING ALPHA-ADRENERG-MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
US8691832B2 (en) * 2010-12-06 2014-04-08 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
MX345400B (es) * 2011-03-15 2017-01-30 Chiesi Farm Spa Derivados de isoxazolidina.
AU2012240246A1 (en) * 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
HRP20200636T1 (hr) 2011-04-29 2020-07-10 The Penn State Research Foundation Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9265765B2 (en) * 2013-03-13 2016-02-23 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
RS66254B1 (sr) 2014-03-31 2024-12-31 Scripps Research Inst Farmakofor koji indukuje trail

Also Published As

Publication number Publication date
CA3158795A1 (en) 2015-10-08
CA2944452A1 (en) 2015-10-08
US10633385B2 (en) 2020-04-28
HUE049013T2 (hu) 2020-08-28
SMT202400497T1 (it) 2025-01-14
EP3662910A1 (en) 2020-06-10
CN106456643A (zh) 2017-02-22
SMT202000219T1 (it) 2020-05-08
US20240190877A1 (en) 2024-06-13
PL3125898T3 (pl) 2020-11-16
KR102473930B1 (ko) 2022-12-05
EP3125898B1 (en) 2019-12-25
EP3125898A1 (en) 2017-02-08
RS60163B1 (sr) 2020-05-29
US20190284188A1 (en) 2019-09-19
SI3125898T1 (sl) 2020-07-31
AU2022283729A1 (en) 2023-02-02
JP2020002170A (ja) 2020-01-09
KR20220163533A (ko) 2022-12-09
FI3662910T3 (fi) 2024-10-31
ES2779979T3 (es) 2020-08-21
WO2015153468A1 (en) 2015-10-08
SI3662910T1 (sl) 2025-05-30
US11891392B2 (en) 2024-02-06
AU2020286314A1 (en) 2021-01-21
US20200283440A1 (en) 2020-09-10
DK3125898T3 (da) 2020-03-30
AU2015241069B2 (en) 2020-10-15
LT3125898T (lt) 2020-04-10
CY1123093T1 (el) 2021-10-29
CA2944452C (en) 2022-07-19
AU2015241069A1 (en) 2016-10-20
PT3662910T (pt) 2024-11-27
PL3662910T3 (pl) 2025-08-11
KR102611067B1 (ko) 2023-12-06
RS66254B1 (sr) 2024-12-31
JP7688245B2 (ja) 2025-06-04
US10239877B2 (en) 2019-03-26
PT3125898T (pt) 2020-04-01
JP6873201B2 (ja) 2021-05-19
US20170107221A1 (en) 2017-04-20
ES2999685T3 (en) 2025-02-26
EP4470617A3 (en) 2025-02-26
EP3125898A4 (en) 2017-08-16
US20220002300A1 (en) 2022-01-06
JP2023022184A (ja) 2023-02-14
EP3662910B1 (en) 2024-09-18
HUE069651T2 (hu) 2025-03-28
DK3662910T3 (en) 2024-11-04
EP4470617A2 (en) 2024-12-04
CN111499636B (zh) 2023-01-13
JP2017511321A (ja) 2017-04-20
HRP20241680T1 (hr) 2025-02-28
CN111499636A (zh) 2020-08-07
JP6756435B2 (ja) 2020-09-16
AU2024204977A1 (en) 2024-08-08
KR20160138513A (ko) 2016-12-05
JP2021119157A (ja) 2021-08-12
JP7186256B2 (ja) 2022-12-08
LT3662910T (lt) 2024-12-27
CN106456643B (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
HRP20200478T1 (hr) Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda
MD3313851T2 (ro) Noi derivați hidroxiester, procedeu pentru prepararea lor și compoziții farmaceutice care îi conțin
CO2019003349A2 (es) Compuestos de benzo[b]tiofeno como agonistas de sting
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EP3494185A4 (en) INKJET INK SET
EP3431075A4 (en) EDARAVONDARREICHUNGSFORM
MA43242A (fr) Mélange pour traiter des engrais à base d'urée
EP2589403A4 (en) DEVICE FOR SUPPORTING AND ATTACHING ANESTHETIC INHALATION
EP3347707A4 (en) REFLECTION IMAGING FOR THE PRECISION AGRICULTURE
EP2720743A4 (en) MASK FOR THE ADMINISTRATION OF A MEDICAMENT TO BE TAKEN
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
IN2014MN02106A (enExample)
PH12016500885A1 (en) Novel heterocyclic compounds
EP3049486A4 (en) INKJET INK SET
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
FR3016938B1 (fr) Attache pour la fixation d'un panneau sur un support
NZ732213A (en) Lanthionine synthetase c-like 2-based therapeutics
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EP3433325A4 (en) INKJET INK SET
AR095097A1 (es) Compuestos de fenoxietoxi
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
JO3742B1 (ar) مركب بيرانو داي بيريدين
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
BR112019001447A2 (pt) método de produção para composto pirazol-amida